RxDoctor Payments Data

Erica Wall

Psychiatric/Mental Health · Chatham, NYNPI 1083152136

Payments from drug & device makers

$1,031in general payments, 2019–2025

Across 19 payments — averaging $54.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$348
  • Neurocrine Biosciences, Inc.$172
  • Otsuka America Pharmaceutical, Inc.$130
  • Lilly USA, LLC$123
  • Supernus Pharmaceuticals, Inc.$123
  • Vanda Pharmaceuticals Inc.$107
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$1,031100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,031 in reported general payments places this provider in the 65th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$7,796
Medicare patients
12
Services billed
95

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole20$31,852
TrintellixVortioxetine Hydrobromide47$23,923
Aripiprazole49$4,462
Clozapine50$2,775
Quetiapine Fumarate63$1,320
Bupropion XlBupropion Hcl52$1,259
Olanzapine23$1,173
Haloperidol Decanoate13$930
Trazodone Hcl95$588
Duloxetine Hcl49$585
Hydroxyzine Hcl26$541
Quetiapine Fumarate ErQuetiapine Fumarate13$511
Fluphenazine Hcl13$435
Venlafaxine Hcl ErVenlafaxine Hcl46$430
Buspirone Hcl43$403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$130$31,85220 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$15$23,92347 claims
Lilly USA, LLCOlanzapine$123$1,17323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Chatham

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →